Sienna Biopharmaceuticals, Inc. (Nasdaq: SNNA), a clinical-stage biopharmaceutical company, today announced that it has commenced a proposed underwritten public offering ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE